SB2054 creates the “Oklahoma Mother and Child Protection Act” and is aimed at restricting abortion-inducing drugs in Oklahoma. The bill defines “abortion” and “abortion-inducing drug,” specifically naming drugs such as mifepristone, misoprostol, and methotrexate when used with the intent to terminate a pregnancy. It generally prohibits manufacturing, distributing, mailing, transporting, delivering, prescribing, or providing abortion-inducing drugs in the state, and also bars aiding or abetting those activities, including financial assistance or transportation connected to obtaining such drugs.
The bill builds a private-enforcement framework centered on qui tam lawsuits. It says the act may be enforced only through qui tam actions brought by private relators, not by the state, local governments, prosecutors, or other public officials. It authorizes suits against people who violate or intend to violate the drug restrictions, while expressly exempting pregnant women, certain federal actors, and some transportation, delivery, and health care-related defendants unless specific conditions are met. It also sets a six-year limitations period, bars class actions, voids waivers of the right to sue, and creates substantial remedies, including injunctive relief, at least $100,000 per violation, and attorney fees for prevailing relators.
The bill would significantly affect Title 63 of the Oklahoma Statutes by adding a new abortion-related chapter and by creating detailed rules on jurisdiction, defenses, immunity, and enforcement. It also attempts to limit the use of Oklahoma’s Citizens Participation Act and Religious Freedom Act in these cases, expands personal jurisdiction over defendants, restricts the application of other states’ laws, and creates a “clawback” mechanism allowing Oklahoma residents to seek damages and injunctions if they are sued elsewhere for conduct protected or authorized under this act. The measure further declares broad sovereign, governmental, and official immunity for the state and its officers in challenges to the act and includes extensive severability language to preserve any surviving portions if parts are struck down.
The overall sentiment reflected in the bill text is strongly anti-abortion and enforcement-oriented, with the legislation framed as a protection measure for mothers and children. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of debate or bipartisan support in the supplied materials. The bill’s structure suggests an intent to make enforcement difficult to block through public litigation and to insulate the statute from constitutional challenges, indicating a highly assertive policy approach.
The main points of contention likely center on the near-total prohibition on abortion-inducing drugs, the use of private qui tam enforcement, and the bill’s efforts to limit judicial review, class actions, and defenses based on constitutional rights, federal law, or other states’ laws. Potentially affected parties include abortion providers, pharmacies, drug manufacturers and distributors, common carriers, courier and rideshare services, health care providers, and anyone assisting in obtaining abortion-inducing drugs. The bill also raises likely concerns about preemption, due process, interstate commerce, and the enforceability of its clawback and immunity provisions.
SB2054 would add a new set of abortion-drug restrictions to Title 63 and create a private-enforcement scheme that bypasses ordinary state enforcement channels. It would prohibit most manufacture, distribution, and provision of abortion-inducing drugs in Oklahoma, authorize private qui tam suits with statutory damages and injunctions, and impose special rules governing jurisdiction, defenses, immunity, and out-of-state judgments. The bill also attempts to limit the reach of other laws, including the Oklahoma Citizens Participation Act and Religious Freedom Act, and to create reciprocal remedies against out-of-state litigation targeting conduct authorized by the act.
The most likely areas of contention are the ban on abortion-inducing drugs, the delegation of enforcement to private qui tam relators, and the bill’s attempt to limit constitutional, statutory, and procedural defenses. Opponents would likely focus on the bill’s impact on medication abortion, its penalties and broad liability for providers and intermediaries, and its efforts to restrict judicial review and the application of other states’ laws. Supporters would likely emphasize protection of unborn children, private enforcement, and the bill’s carveouts for life-threatening conditions, ectopic pregnancies, miscarriage management, and certain federal or protected conduct.